Advanced Enzyme Technologies Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 4/6
Advanced Enzyme Technologies's earnings have been declining at an average annual rate of -1.3%, while the Chemicals industry saw earnings growing at 15.6% annually. Revenues have been growing at an average rate of 7.3% per year. Advanced Enzyme Technologies's return on equity is 10.4%, and it has net margins of 22%.
Anahtar bilgiler
-1.3%
Kazanç büyüme oranı
-1.4%
EPS büyüme oranı
Chemicals Sektör Büyümesi | 17.7% |
Gelir büyüme oranı | 7.3% |
Özkaynak getirisi | 10.4% |
Net Marj | 22.0% |
Sonraki Kazanç Güncellemesi | 09 Nov 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
After Leaping 26% Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Shares Are Not Flying Under The Radar
Aug 20We Think Shareholders Are Less Likely To Approve A Pay Rise For Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) CEO For Now
Jul 19Advanced Enzyme Technologies (NSE:ADVENZYMES) Has Affirmed Its Dividend Of ₹1.00
Jul 13Advanced Enzyme Technologies' (NSE:ADVENZYMES) Returns On Capital Not Reflecting Well On The Business
Apr 08Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends
Sep 23Advanced Enzyme Technologies (NSE:ADVENZYMES) Could Be Struggling To Allocate Capital
Feb 03Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends
Aug 11With EPS Growth And More, Advanced Enzyme Technologies (NSE:ADVENZYMES) Is Interesting
May 13Returns On Capital At Advanced Enzyme Technologies (NSE:ADVENZYMES) Paint A Concerning Picture
Mar 28The Advanced Enzyme Technologies (NSE:ADVENZYMES) Share Price Has Gained 185%, So Why Not Pay It Some Attention?
Mar 13Don't Ignore The Fact That This Insider Just Sold Some Shares In Advanced Enzyme Technologies Limited (NSE:ADVENZYMES)
Feb 21Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Feb 18I Built A List Of Growing Companies And Advanced Enzyme Technologies (NSE:ADVENZYMES) Made The Cut
Feb 03What Kind Of Investors Own Most Of Advanced Enzyme Technologies Limited (NSE:ADVENZYMES)?
Jan 19What Do The Returns On Capital At Advanced Enzyme Technologies (NSE:ADVENZYMES) Tell Us?
Dec 28The Advanced Enzyme Technologies (NSE:ADVENZYMES) Share Price Has Gained 114%, So Why Not Pay It Some Attention?
Dec 13Have Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Insiders Been Selling Their Stock?
Nov 28Are Strong Financial Prospects The Force That Is Driving The Momentum In Advanced Enzyme Technologies Limited's NSE:ADVENZYMES) Stock?
Nov 20Here's Why I Think Advanced Enzyme Technologies (NSE:ADVENZYMES) Might Deserve Your Attention Today
Nov 05What You Need To Know About Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) Investor Composition
Oct 21Have Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Insiders Been Selling Their Stock?
Oct 06Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Stocks Shoot Up 31% But Its P/E Still Looks Reasonable
Sep 26Gelir ve Gider Dağılımı
Advanced Enzyme Technologies nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Jun 24 | 6,311 | 1,386 | 1,394 | 0 |
31 Mar 24 | 6,239 | 1,333 | 1,361 | 0 |
31 Dec 23 | 6,048 | 1,371 | 1,327 | 0 |
30 Sep 23 | 5,859 | 1,248 | 1,296 | 0 |
30 Jun 23 | 5,668 | 1,166 | 1,257 | 0 |
31 Mar 23 | 5,406 | 1,056 | 1,217 | 0 |
31 Dec 22 | 5,337 | 979 | 1,167 | 0 |
30 Sep 22 | 5,251 | 960 | 1,131 | 0 |
30 Jun 22 | 5,135 | 995 | 1,111 | 0 |
31 Mar 22 | 5,294 | 1,196 | 1,099 | 0 |
31 Dec 21 | 5,309 | 1,268 | 1,040 | 0 |
30 Sep 21 | 5,350 | 1,424 | 1,000 | 0 |
30 Jun 21 | 5,325 | 1,500 | 930 | 0 |
31 Mar 21 | 5,018 | 1,459 | 898 | 0 |
31 Dec 20 | 4,820 | 1,459 | 891 | 0 |
30 Sep 20 | 4,569 | 1,364 | 868 | 0 |
30 Jun 20 | 4,481 | 1,301 | 859 | 0 |
31 Mar 20 | 4,440 | 1,293 | 852 | 0 |
31 Dec 19 | 4,480 | 1,302 | 871 | 0 |
30 Sep 19 | 4,366 | 1,210 | 900 | 0 |
30 Jun 19 | 4,288 | 1,148 | 891 | 0 |
31 Mar 19 | 4,220 | 1,111 | 888 | 0 |
31 Dec 18 | 4,194 | 1,061 | 873 | 0 |
30 Sep 18 | 4,261 | 1,068 | 838 | 0 |
30 Jun 18 | 4,199 | 1,039 | 737 | 0 |
31 Mar 18 | 3,918 | 901 | 752 | 0 |
31 Dec 17 | 3,660 | 837 | 687 | 0 |
30 Sep 17 | 3,213 | 725 | 624 | 0 |
30 Jun 17 | 3,127 | 793 | 592 | 0 |
31 Mar 17 | 3,290 | 915 | 546 | 0 |
31 Dec 16 | 3,260 | 942 | 536 | 0 |
30 Sep 16 | 3,404 | 998 | 521 | 0 |
30 Jun 16 | 3,184 | 854 | 489 | 0 |
31 Mar 16 | 2,938 | 759 | 486 | 0 |
31 Mar 15 | 2,233 | 510 | 401 | 0 |
31 Mar 14 | 2,397 | 201 | 365 | 0 |
Kaliteli Kazançlar: ADVENZYMES has high quality earnings.
Büyüyen Kar Marjı: ADVENZYMES's current net profit margins (22%) are higher than last year (20.6%).
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: ADVENZYMES's earnings have declined by 1.3% per year over the past 5 years.
Büyüme Hızlandırma: ADVENZYMES's earnings growth over the past year (18.9%) exceeds its 5-year average (-1.3% per year).
Kazançlar vs. Sektör: ADVENZYMES earnings growth over the past year (18.9%) exceeded the Chemicals industry 10.4%.
Özkaynak Getirisi
Yüksek ROE: ADVENZYMES's Return on Equity (10.4%) is considered low.